- An adjunct medical professor at Johns Hopkins Hospital has challenged the FDA's 2011 approval of AstraZeneca's anticlotting drug Brilinta, the WSJ reports.
- Using the federal False Claims Act, Victor Serebruany has filed a complaint arguing that data was manipulated in a trial which showed that the medicine saved lives and cut heart attacks. The U.S. attorney's office in Washington DC is investigating the conduct of the trial.
- Separately, AstraZeneca (AZN) has completed the acquisition of Bristol-Myers Squibb's (BMY) holding in the companies' diabetes joint venture for an initial $2.7B and as much as $1.65B in additional payments, as well as royalties on sales. (PR)